Revenue: As of FY2025 Q1, the actual value is USD 104.41 M.

EPS: As of FY2025 Q1, the actual value is USD -0.21.

Segment Revenue

• Consolidated Revenue: $104.4 million, an increase of 10.3% from $94.7 million compared to the prior year quarter.
• Patient Services Revenue: $53.1 million, up 1.2% compared to Q1 2024.
• Dispensary Revenue: $49.3 million, an increase of 24.2% compared to Q1 2024.

Operational Metrics

• Gross Profit: $17.2 million, an increase of 44.1% compared to the prior year quarter.
• Net Loss: $19.6 million compared to $19.9 million for the prior year quarter.
• Adjusted EBITDA: - $5.1 million compared to - $10.9 million for the prior year quarter.
• SG&A Expenses: $25.4 million or 24.3% of revenue, compared with $28.5 million or 30.1% of revenue in Q1 2024.

Cash Flow

• Net Cash and Cash Equivalents Used in Operating Activities: - $5.0 million for Q1 2025.
• Free Cash Flow: - $4.0 million, compared to - $15.4 million in Q1 2024.

Unique Metrics

• Retail Pharmacy and Dispensary Revenue: $49.3 million, contributing over $9 million in gross profit in Q1.

Outlook / Guidance

• The Oncology Institute reaffirms its full year 2025 guidance with expected revenue between $460 to $480 million, gross profit between $73 to $82 million, adjusted EBITDA between - $8 to - $17 million, and free cash flow between - $12 to - $21 million.
• The company anticipates new capitation contracts in the first half of 2025 projected to add approximately $50 million in new revenue on an annualized basis.
• TOI expects adjusted EBITDA of approximately - $4 to - $5 million in the second quarter of 2025 due to stabilization of contracts and initial lower encounter volumes.